|
|
|
| Research progress on the relationship between fusobacterium nucleatum and colorectal cancer |
| CHENG Yu1 TAN Shiyun2 LI Ming2 Ma Fengmei1 |
1.The First Clinical Medical College, Wuhan University, Hubei Province, Wuhan 430060, China;
2.Department of Gastroenterology Hubei Key laborary of Digestive System Disease, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
Abstract Colorectal Cancer (CRC) has high incidence and mortality. Fusobacterium nucaleatum (Fn) is closely related to the occurrence, development and drug resistance of CRC, however, the mechanism is not clear. This paper intends to explore mechanisms from inflammation, immunity, phenotypic inheritance, metabolism, drug resistance and so on. Moreover, Fn can also be used as a new biomarker in the clinical diagnosis of CRC, while fecal test, serological test and electrospray ionization mass spectrometry are of great value in clinical diagnosis. At the same time, antibiotic treatment and vaccine therapy for Fn provide a new direction for the treatment of CRC. This article reviews the mechanism of pathogenesis, drug resistance, the diagnostic value and the treatment of CRC caused by Fn.
|
|
|
|
|
|
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Garrett WS. Cancer and the microbiota [J]. Science，2015， 348（6230）：80-86.
[3] Brennan CA，Garrett WS. Fusobacterium nucleatum-symbiont，opportunist and oncobacterium [J]. Nat Rev Microbiol，2019，17（3）：156-166.
[4] Kostic AD，Gevers D，Pedamallu CS，et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma [J]. Genome Res，2012，22（2）：292-298.
[5] Castellarin M，Warren RL，Freeman JD，et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma [J]. Genome Res，2012，22（2）：299-306.
[6] Komiya Y，Shimomura Y，Higurashi T，et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity [J]. Gut，2019，68（7）：1335-1337.
[7] Kostic AD，Chun E，Robertson L，et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment [J]. Cell Host Microbe，2013，14（2）：207-215.
[8] Rubinstein MR，Wang X，Liu W，et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin [J]. Cell Host Microbe，2013，14（2）：195-206.
[9] Gur C，Ibrahim Y，Isaacson B，et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack [J]. Immunity，2015，42（2）：344-355.
[10] Abed J，Emgard JE，Zamir G，et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc [J]. Cell Host Microbe，2016，20（2）：215-225.
[11] Gur C，Maalouf N，Shhadeh A，et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CE-ACAM1 [J]. Oncoimmunology，2019，8（6）：e1581531.
[12] Chen T，Li Q，Wu J，et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism [J]. Cancer Immunol Immunother，2018，67（10）：1635-1646.
[13] Tahara T，Yamamoto E，Suzuki H，et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma [J]. Cancer Res，2014，74（5）：1311-1318.
[14] Hashemi GN，Heidarzadeh S，Jahangiri S，et al. Fusobacterium nucleatum and colorectal cancer：A mechanistic overview [J]. J Cell Physiol，2019，234（3）：2337-2344.
[15] Ito M，Kanno S，Nosho K，et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway [J]. Int J Cancer，2015，137（6）：1258-1268.
[16] Mima K，Sukawa Y，Nishihara R，et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma [J]. JAMA Oncol，2015，1（5）：653-661.
[17] Park HE，Kim JH，Cho NY，et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma [J]. Virchows Arch，2017， 471（3）：329-336.
[18] Yang Y，Weng W，Peng J，et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kappaB，and Up-regulating Expression of MicroRNA-21 [J]. Gastroenterology，2017，152（4）：851-866.
[19] Hellmich MR，Szabo C. Hydrogen Sulfide and Cancer [J]. Handb Exp Pharmacol，2015，230：233-241.
[20] Kezuka Y，Ishida T，Yoshida Y，et al. Structural insights into the catalytic mechanism of cysteine（hydroxyl）lyase from the hydrogen sulfide-producing oral pathogen，Fusobacterium nucleatum [J]. Biochem J，2018，475（4）：733-748.
[21] Scharlau D，Borowicki A，Habermann N，et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre [J]. Mutat Res，2009，682（1）：39-53.
[22] Kostic AD，Chun E，Robertson L，et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment [J]. Cell Host Microbe，2013，14（2）：207-215.
[23] Zhang S，Yang Y，Weng W，et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer [J]. J Exp Clin Cancer Res，2019，38（1）：14.
[24] Yu T，Guo F，Yu Y，et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy [J]. Cell，2017，170（3）：548-563.
[25] Tunsjo HS，Gundersen G，Rangnes F，et al. Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients [J]. Eur J Clin Microbiol Infect Dis，2019，38（7）：1367-1376.
[26] Wong SH，Kwong T，Chow TC，et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia [J]. Gut，2017， 66（8）：1441-1448.
[27] Liang Q，Chiu J，Chen Y，et al. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer [J]. Clin Cancer Res，2017，23（8）：2061-2070.
[28] Wang HF，Li LF，Guo SH，et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer [J]. Sci Rep，2016，6：33440.
[29] Nagalingam S，Lisgaris M，Rodriguez B，et al. Identification of occult Fusobacterium nucleatum central nervous system infection by use of PCR-electrospray ionization mass spectrometry [J]. J Clin Microbiol，2014，52（9）：3462-3464.
[30] Bullman S，Pedamallu CS，Sicinska E，et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer [J]. Science，2017，358（6369）：1443-1448.
[31] Guo SH，Wang HF，Nian ZG，et al. Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract [J]. Sci Rep，2017，7（1）：10566. |
|
|
|
